News from ATAI and Neuronasal
Category: Industry News
Spravato®▼ (Esketamine) Nasal Spray authorised in Europe for Adults with Treatment-Resistant Major Depressive Disorder
Industry news from Janssen
Fampyra® (fampridine) becomes first symptomatic treatment in Wales to receive a recommendation for funding as an option for walking impairment in adult patients with all types of multiple sclerosis (MS)
Industry news from Biogen
Grifols presents latest Alzheimer’s clinical trial data
Neuroimaging shows AMBAR clinical trial’s positive effects in patients with mild-to-moderate Alzheimer’s disease
Creating clinical leaders, transformation pioneers and innovation specialists: because change starts from the ground up
Those of us in the room have the power we need to fundamentally improve the quality of multiple sclerosis (MS) care in the UK, reduce variation and offer consistent care at the level we want everywhere, in the next 3 years. In July, 85% of 120 healthcare professionals agreed with this statement (‘Raising the Bar’,…
Multiple Sclerosis Patients in the UK to Receive Accelerated Access to MAVENCLAD® (Cladribine Tablets) Following Fast Tracked NICE Guidance Update
Industry news: patients with highly active MS will now have access to cladribine tablets without the additional requirement of a gadolinium-enhanced MRI, following review from NICE.
A Manifesto for being InCredible
News about the BNA’s campaign, ‘Credibility in Neuroscience’, an important programme to drive open, transparent and reproducible research.
PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements
News from PTC Therapeutics, Inc.
EMA approves interferon beta treatments, including Rebif (interferon beta-1a), for relapsing MS patients during pregnancy and breastfeeding
News from Merck
